About Qiyang Medical Group
A full-chain overseas expansion service provider built on Health Technology Assessment (HTA) β from evidence generation, market access & registration, to reimbursement negotiation and commercialization.
π― Mission
To take every high-quality domestic medical product from China to global markets.
π Vision
Aligned with UN SDG target 3.8 β achieve Universal Health Coverage, so everyone has access to safe, effective, quality and affordable essential medicines and vaccines.
π€ Culture
"When the world is unwell, Qiyang brings the cure" β a reliable partner for Chinese healthcare going global.
An overseas expansion service provider focused on global reimbursement access
Qiyang Medical Group began validating its approach in 2022 and formally established operations in Suzhou Industrial Park in June 2026. The company focuses on overseas reimbursement market access, providing domestic pharma and medical-device companies full-chain overseas services covering market-access pathway analysis, government tendering, and pricing & negotiation support.
Facing the industry's core challenge β "China has the world's second-largest generic capacity yet lacks health-economic evidence to enter overseas reimbursement systems" β Qiyang uses health-economic evidence and local execution to bridge the gap between manufacturing capability and overseas reimbursement listing.
The group is driven by two founding tracks: one focused on pharmaceutical overseas expansion & global reimbursement access, the other building the Qiyang No.1 / No.2 / No.3 digital product lines (health management, medical-economics SaaS, and a global HTA platform), linking health-economics methodology across both services and products. See our founding team.
Our approach: translating a company's commercial ask into the language of overseas government goals (SDG 3.8 / Universal Health Coverage), connecting China's supply capacity with the global access gap.
Strategic direction
- Fill the gap left by traditional consultancies in links 4β5 of the chain (market access, reimbursement negotiation).
- Build on HTA, covering evidence β access/registration β reimbursement negotiation β commercialization.
- Offer Chinese pharma a "low upfront cost, results-based" path overseas.
Five tactics
- Evidence Β· AI-driven automated evidence systems
- Market access Β· localized full-process access support
- Commercialization Β· phased rights sale & ongoing operation
- Resource integration Β· global expert network & strategic partnerships
- Pricing Β· health-economics-driven precision pricing
Core business covering the full overseas chain
Own the complete loop from evidence generation to commercialization β so the old dilemma of "a report with no one to execute it" no longer applies.
HTA Assessment
Evidence generation & health-economic modelling
Access & Registration
Target-country registration & market-access pathway
Reimbursement Negotiation
Pricing strategy & payer negotiation support
Commercialization
Local promotion & commercialization
Ongoing Maintenance
Listing maintenance & long-term access
Filling the "missing links": traditional consultancies fall short in market access and reimbursement negotiation β clients often get an HTA report and then "hit a wall". Qiyang's specialists deliver localized CEA/BIA modelling, ICER threshold analysis and budget-impact simulation, and handle dossier preparation and expert defense β accurate, fast and effective.
Business model: subsidiaries built around business lines
Qiyang structures the group around "one business line, one operating entity" β professional subsidiaries for different businesses and target markets give overseas services real, executable, on-the-ground delivery rather than remote support from a parent office.
Suzhou Β· Qiyang Medical (Group HQ / overseas platform)
- Advancing partnerships in the South African market.
- HTA/CEA modelling collaboration with Thailand HITAP.
- Strategic collaboration with Middle East Bridge to advance GCC / Saudi access.
- Ongoing collaboration with multiple Chinese generic-drug companies.
Hong Kong Β· Qiyang
- Full Hong Kong government tendering process.
- HTA review & price negotiation.
Saudi Arabia Β· Qiyang
- Access to Arab family networks and Saudi royal-family China partnerships.
- Local access via the GCC market-service network.
United States Β· Qiyang
- US market analysis & BD strategy for a DPP-4 chronic-disease product.
- Layered PBM / Medicare / Medicaid access pathways.
Chengdu Β· Qiyang AI Service Center
- Invited to operate in Chengdu Hi-tech Zone.
- Health-economic modelling (HEOR / CEA / BIA) & AI data services.
How it fits together
Group HQ centrally provides methodology and resources; each subsidiary independently carries access, tendering, negotiation and commercialization by business/region, delivered through local partner networks (Middle East Bridge, Thailand HITAP, etc.).
Where policy and demand meet β a historic window
UN SDG 3.8 (Universal Health Coverage), WHO's "three billion" workplan, and Healthy China 2030 β global health agendas are moving in step with China's healthcare upgrade, releasing sustained policy tailwind for going global.
- ~1/3 of the world lacks access to essential medicines; lower/middle-income countries carry ~90% of disease burden.
- Chinese pharma exports have long stayed at 1%β2% of total exports β supply capacity is far from becoming global access.
- Speaking the language of overseas governments' SDG goals is becoming the key that opens access.
Understand this opportunity
Industry pain points, the global supply-demand gap and priority markets.
View global opportunityWhy Qiyang: another option at the same decision point
| Industry player | Typical capability & boundary | Difference from Qiyang |
|---|---|---|
| CRO / CDMO | Contract R&D and manufacturing β focused on R&D/production, no market access or commercialization. | Qiyang focuses on overseas market access β a different decision point, not R&D/manufacturing. |
| Regulatory consultancy | Registration and regulatory compliance; stops at approval, no reimbursement or commercialization. | Qiyang adds health-economic evidence and reimbursement negotiation beyond registration. |
| Distributor / wholesaler | Local distribution and sales β needs already-approved products, no upstream evidence generation. | Qiyang engages from the evidence-generation end, not just distribution. |
| Traditional consultancy | Market research and strategy reports β no end-to-end execution, output is only advice. | Qiyang takes on execution and is paid on sales results. |
| Private equity / licensing | Product licensing and equity investment β often requires transferring product rights. | Qiyang does not take equity; producers keep product ownership. |
Qiyang's distinct position: end-to-end execution (evidence β registration β reimbursement β commercialization) Β· no equity transfer (producers keep ownership and 40% of ex-factory supply revenue) Β· results-based pay (revenue share; Qiyang profits only when products actually sell) Β· HTA core capability (health-economic evidence recognized by government bodies such as Thailand HITAP).
Six supporting systems
Academic advisory system
Global health-economic and HTA experts for methodology and international-standard assurance.
Core technical team
Focused on health-economics R&D and HTA report writing, fluent in AMCP / NICE formats.
Specialty medical system
Disease-type coverage and mature clinical pathways for real clinical context.
Business development system
Global government health-economics expert network; identifying quality drugs and reimbursement negotiation.
Advanced technology system
AI-driven big-data models for overseas analysis and evidence automation.
Financial management system
Sound financial planning supporting multi-year capital use and long-horizon delivery.
International network: collaborations with leading global health-economics & policy institutions β including Thailand HITAP, GCC policy-access networks, and government health-policy expert resources across Hong Kong, Japan and Singapore.
Learn what Qiyang can do for you
From single-product assessments to full-chain overseas delivery β talk to us.
View overseas services Contact us